HLX10: This study is comparing the effectiveness of chemotherapy and radiation therapy when given with or without a new targeted therapy (HLX10) in people with limited-stage small cell lung cancerA Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Summary

Eligible participants will be randomly allocated to either the Experimental Arm or the Placebo Comparator Arm. All participants will receive active treatment. In the Experimental Arm, participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) plus HLX10 (300mg) every three weeks, at the same time as receiving standard thoracic radiation therapy. In the Placebo Comparator Arm, participants will receive 4 cycles of standard-of-care chemotherapy (carboplatin/cisplatin-etoposide) plus a placebo every 3 weeks, at the same time as receiving thoracic radiation therapy.

Conditions

This trial is treating patients with small cell lung cancer.

More information